Valneva's Regulatory Milestone Arrives as the Market Waits on a Second-Half Revenue Rebound

EMA validates Valneva's Lyme vaccine application; H1 sales miss pace, but guidance held. First Berlin keeps Buy with €4.40 target.

The European Medicines Agency has formally accepted Valneva's marketing application for PF-07307405, the Lyme disease vaccine candidate co-developed with Pfizer — a validation that shifts the program from submission to substantive review. The regulatory green light, built on positive Phase 3 data from the VALOR study, landed in the same week the Franco-Austrian biotech posted its first-half numbers, giving investors a rare moment where pipeline promise and financial reality shared the spotlight.

The company's interim report, released on August 13, showed product sales of €64.0 million for the first six months of 2026. That figure sits well below the pace implied by management's full-year guidance of €135 million to €150 million in product revenue, with total revenue projected between €145 million and €160 million. Valneva nevertheless reaffirmed those targets unchanged, a stance that implicitly banks on a sharp acceleration in the second half.

That expectation of a sales comeback is precisely what First Berlin Equity Research latched onto when it reiterated its Buy rating in late August. The brokerage trimmed its twelve-month price target from €4.50 to €4.40, a modest adjustment that analysts attributed primarily to the soft second-quarter product sales rather than any deterioration in the pipeline story. The note underscored that the anticipated H2 rebound remains the central pillar of the bull case.

The company exited June with €121.5 million in cash, a buffer that buys time while several clinical programs run in parallel. Management has also consolidated all research and development activities in Vienna, a move designed to streamline operations and trim costs over the longer term without pausing investment across the Lyme, Shigella, and existing travel vaccine franchises.

On the Shigella front, media reports point to Phase II safety data in infants and results from a human challenge study landing in the third quarter of 2026. Positive readouts would add another layer to a portfolio increasingly weighted toward partnerships with larger pharmaceutical players.

The market's response to the EMA validation has been measured. The shares closed Monday at €2.89, down 2.0 percent on the day and 2.0 percent lower over the trailing seven sessions. The stock still trades roughly 23 percent above its 50-day moving average of €2.36, reflecting the recovery that has built over recent weeks. But the gap to the 200-day average of €3.23 remains a 9.7 percent climb, underscoring that the bounce has yet to erase last year's losses. From the 52-week high of €5.34, reached on October 1, 2025, the shares remain about 46 percent lower, and the year-to-date decline stands at 22 percent.

First Berlin's €4.40 target implies substantial upside from current levels, but that conviction rests on a specific assumption: that the second half delivers the revenue acceleration baked into management's guidance. With the EMA now formally reviewing the Lyme dossier, the regulatory clock is ticking — but so is the commercial one.